Table 1B.

Study Results

Study #	Author	Mean Baseline Cr, NAC Group(mg/dl)	Mean Baseline Cr, Control Group(mg/dl)	Mean change in Cr, NAC Group(mg/dl)	Mean change in Cr, Control Group(mg/dl)	Mean Difference Change in Creatinine†	% CIN NAC/Controls	RR of CIN	Patients Needing Dialysis NAC/Controls, N	Reason for Exclusion
1	Kay	1.35	1.36	−0.13	+0.02	−0.15	3.9/12.2	0.32	0
2	Baker	1.85	1.75	−0.08	0.05	−0.14	4.9/20.4	0.24	0
3	Shyu	2.80	2.80	−0.29	+0.24	−0.53	3.3/24.6	0.14	0/1
4	Ochoa*	2.00	1.87	0.06	+0.23	−0.17	11.1/25.0	0.44	0
5	Durham	2.20	2.30	‡	‡	N/A	26.3/22.0	1.20	‡
6	Diaz-Sandoval	1.66	1.56	−0.10	+0.30	−0.4	8.0/44.8	0.18	‡
7	Briguori	1.52	1.54	−0.04	−0.01	−0.03	6.5/11.0	0.59	0/1
8	Allaqaband	2.20	2.03	0.01	+0.09	−0.08	17.8/15.0	1.19	‡
9	Tepel	2.50	2.40	−0.40	+0.20	−0.6	2.4/21.4	0.11	0
10	Boccalandro	1.80	1.90	0.17	+0.19	−0.02	13.7/12.3	1.12	‡	Not randomized
11	Vallero	‡	‡	‡	‡	N/A	‡	N/A	‡	Groups separated by Cr, varying definitions of CIN
12	Mouhayar*	2.00	1.80	−0.40	0.10	−0.5	‡	N/A	‡	Not randomized
13	Kahlon*	2.16	2.07	‡	‡	N/A	‡	N/A	‡	Outcomes not reported
14	Erickson*	‡	‡	‡	‡	N/A	30/20	1.69	6/1	Not randomized
15	Adamian*	1.89	1.96	−0.01	+0.52	−0.53	2.9/36.4	0.08	1/3	Not randomized

^*Articles found only in abstract form.

^†Negative values mean improvement in creatinine in NAC group compared to control group.

^‡Value unclear from provided data.

CIN, contrast-induced nephropathy; NAC, N-acetylcysteine; RR, relative risk; Cr, creatinine.

Studies included in the analysis are listed above the solid line, while excluded studies are listed below the solid line. All studies assessed time to outcome at 48 hours except Kahlon et al.³⁰, which assessed outcome at 96 hours. Briguori et al⁴¹ and Bader et al.⁴⁰ are not included in the table because they both had another active treatment arm, but no control group.